Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | WRN | Q14191 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558062 | 0.78 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP2C19BLMHPGD | |
| SCHEMBL11510545 | 0.78 | CYP1A2 (0.34) | ALDH1A1CYP1A2CYP2C19BLMHPGD | |
| SCHEMBL2581743 | 0.77 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C19BLMHPGD | |
| SCHEMBL269178 | 0.77 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C19BLMHPGD | |
| SCHEMBL1245548 | 0.77 | MMP1 (0.36) | ALDH1A1MMP1MMP2MMP3MMP9 | |
| SCHEMBL20934272 | 0.76 | PTGS1 (0.36) | ALDH1A1CYP1A2CYP2C19BLMHPGD | |
| SCHEMBL28981237 | 0.76 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP2C19BLMHPGD | |
| SCHEMBL31463689 | 0.75 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C19MAPTCYP2C9 | |
| SCHEMBL714989 | 0.74 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C19BLMHPGD | |
| SCHEMBL1564922 | 0.74 | CYP2D6 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10576164-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20190247510-A1 | DLL3 MODULATORS AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190070305-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | IMMUNOGEN, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20190000969-A1 | NOVEL ANTI-UPK1B ANTIBODIES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180125997-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
| US-9821074-B2 | Pyrrolobenzodiazepines and conjugates thereof | GENENTECH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170266312-A1 | ANTI-DLL3 ANTIBODY DRUG CONJUGATES | ABBVIE STEMCENTRX LLC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266312-A1 | ANTI-DLL3 ANTIBODY DRUG CONJUGATES | ABBVIE STEMCENTRX LLC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9649390-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2017-05-16 | — | — | US | disclosed |
| US-9555125-B2 | Benzodiazepines and conjugates thereof | IMMUNOGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170000901-A1 | DLL3 MODULATORS AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160175460-A1 | ENGINEERED ANTI-DLL3 CONJUGATES AND METHODS OF USE | STEMCENTRX, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160144052-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2016-05-26 | — | — | US | disclosed |
| US-20160075779-A1 | DLL3 MODULATORS AND METHODS OF USE | STEMCENTRX, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160031887-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9155803-B1 | Anti-DLL3 antibody drug conjugates and methods of use | STEMCENTRX, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150209444-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20140294868-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160144052-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BCR, GABRA3 | ALDH1A1 738/4885CYP1A2 111/4885CYP2C19 43/4885 |
| US-20170000901-A1 | DLL3 MODULATORS AND METHODS OF USE | DLK1, PDLIM5, PDCD1LG2 | ALDH1A1 3680/4885CYP1A2 4881/4885CYP2C19 4884/4885 |
| US-10576164-B2 | Pyrrolobenzodiazepines and conjugates thereof | CHRM1, NPSR1, CHRM4 | ALDH1A1 1949/4885CYP1A2 1039/4885CYP2C19 1092/4885 |
| US-20150209444-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | GABBR1, GABRA1, GABBR2 | ALDH1A1 246/4885CYP1A2 177/4885CYP2C19 121/4885 |
| US-20140294868-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CHRM1, CHRM4, CHRM2 | ALDH1A1 2065/4885CYP1A2 1013/4885CYP2C19 1105/4885 |
| US-20160175460-A1 | ENGINEERED ANTI-DLL3 CONJUGATES AND METHODS OF USE | DYNLL1, DLK1, DYNLL2 | ALDH1A1 979/4885CYP1A2 4843/4885CYP2C19 4853/4885 |
| US-20180125997-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CHRM1, NPSR1, CHRM4 | ALDH1A1 1940/4885CYP1A2 1033/4885CYP2C19 1092/4885 |
| US-20190247510-A1 | DLL3 MODULATORS AND METHODS OF USE | DLK1, PDLIM5, PDCD1LG2 | ALDH1A1 3680/4885CYP1A2 4881/4885CYP2C19 4884/4885 |
| US-20160075779-A1 | DLL3 MODULATORS AND METHODS OF USE | DLK1, PDLIM5, PDCD1LG2 | ALDH1A1 3680/4885CYP1A2 4881/4885CYP2C19 4884/4885 |
| US-20170266312-A1 | ANTI-DLL3 ANTIBODY DRUG CONJUGATES | DLK1, DYNLL1, DYNLL2 | ALDH1A1 2158/4885CYP1A2 4748/4885CYP2C19 4867/4885 |
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BOD1L1, GABRA1 | ALDH1A1 974/4885CYP1A2 2715/4885CYP2C19 2352/4885 |
| US-20190070305-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | GABBR1, GABRA1, GABBR2 | ALDH1A1 246/4885CYP1A2 177/4885CYP2C19 121/4885 |
| US-20190000969-A1 | NOVEL ANTI-UPK1B ANTIBODIES AND METHODS OF USE | UCK2, DCK, TTBK1 | ALDH1A1 3426/4885CYP1A2 4865/4885CYP2C19 4878/4885 |
| US-20160031887-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | GABRA3, GABRA4, AVPR1B | ALDH1A1 450/4885CYP1A2 64/4885CYP2C19 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.